The drugmaker Novo Nordisk is slated to report its second-quarter financial results early Wednesday, after shares plunged ...

The market is driving prices on GLP-1 drugs down, and an added benefit is lower spending on food.

Levi & Korsinsky is representing the shareholder plaintiff in a suit claiming the Ozempic and Wegovy manufacturer withheld ...

Muscle and strength loss in human aging, also known as sarcopenia, can result in trouble with balance and walking, according to the Cleveland Clinic. It’s a condition often linked to obesity, ...

Novo Nordisk (NVO) files additional court cases against vendors selling cheaper semaglutide knockoffs. Read more here.

Weston's downgrade still values Novo Nordisk stock above its current share price of $47 and change, however. Moreover, Novo ...

The online weight loss company launches a $119 starter plan using low-dose semaglutide and behavioral coaching to improve ...

For outsourcing and manufacturing professionals, 2024 may be remembered as the year capacity and partnerships took center ...

The telehealth company posted revenue of $544.8 million in the second quarter, marking a 73% increase year over year but missing analyst estimates for $552 million, according to Bloomberg data. Hims & ...

Novo Nordisk is scheduled to report results for the second quarter on Wednesday. Here is what you need to know: PROFIT FORECAST: The company pre-released preliminary second-quarter numbers last week, ...

Choice of therapy to control high blood sugar may affect survival among older adults with cancer and type 2 diabetes, according to study results.Those who used GLP-1 receptor agonists exhibited ...

The company has big ambitions. It wants to reach at least $6.5 billion in sales by 2030. In the short term, as it tries to steer its consumers to high-end daily products, Chief Financial Officer Yemi ...